Powell

Researchers are evaluating a fixed-dose combination of lifitegrast and perfluorohexyloctane eye drops to study their effects on signs and symptoms of dry eye disease. This Phase 2, randomized, double-masked, parallel-group, active-controlled, multicenter study aims to assess the safety and efficacy of treatments administered twice daily over four weeks. The study includes adults aged 18 and older who have experienced dry eye disease symptoms for at least six months. Participants will be assigned randomly to one of six groups receiving either the lifitegrast/perfluorohexyloctane combination, lifitegrast alone, perfluorohexyloctane alone, or a placebo vehicle. All treatments consist of topical ocular drops administered twice daily for four weeks. The study compares the combination therapy with individual drugs and placebo to evaluate their effects on dry eye disease. During the study, participants will undergo assessments including corneal fluorescein staining to measure changes from baseline over 29 days. Researchers will monitor signs and symptoms of dry eye disease at screening, baseline, and throughout the treatment period. Participants are expected to follow all trial instructions and attend visits for evaluations to track treatment impact and safety.

Researchers are evaluating the effectiveness and safety of IPN10200, a treatment for moderate to severe glabellar lines, which are wrinkle-like lines between the eyebrows. The study focuses on adult participants and includes both a double-blind phase comparing a single dose of IPN10200 to placebo, and an open-label phase assessing repeat doses over time. The study aims to understand how well IPN10200 works and how safe it is for improving these facial lines. Participants may receive IPN10200 or placebo injections into specific muscles in the glabellar region during the double-blind phase. In the open-label phase, new participants and those rolling over from the double-blind phase may receive IPN10200 for up to four treatment cycles. The study includes a screening period of up to 20 days, a treatment period with multiple visits in the first month followed by monthly visits, and a 24-week follow-up after the last injection to monitor health. Throughout the study, participants will have health assessments including blood tests, physical exams, clinical evaluations, and ECGs. They will also complete questionnaires and keep diaries. Researchers will measure treatment response at specific weeks using scales that evaluate wrinkle severity and participant satisfaction. Safety and long-term effects including antibody development and adverse events will be closely monitored. Each participant may be involved for up to 107 weeks and can withdraw at any time.

Researchers are evaluating the Balanced Progressive Intensity Training (BPIT) 5-Line Principle, a 5-week supervised exercise program designed for healthy adults aged 18 to 65 years. The study focuses on how this training method influences functional movement efficiency, joint mobility, postural control, strength adaptation, and heart rate variability while tracking safety and individual responses to exercise intensity. Participants will engage in 3 to 5 supervised BPIT sessions per week, progressing through five levels of intensity based on anatomical landmarks and ground reaction forces. These levels include Ground-Based (Low), Knee-Level (Low-Moderate), Standing (Moderate), Head-Level (Moderate-High), and Plyometric (High-Impact) training. The entire program lasts five weeks, applying a structured increase in exercise challenge. Throughout the study, participants will undergo assessments at baseline and after five weeks, including functional movement screening, balance tests, strength measures, joint range of motion, and pain evaluation. Weekly monitoring will track resting heart rate variability and any training-related discomfort or minor injuries. The study aims to measure improvements in movement efficiency and neuromuscular adaptation while ensuring participant safety during the training period.

Researchers are evaluating the safety and effectiveness of the DG1 spectacle lens in slowing the progression of myopia in children aged 7 to 10 years. The study aims to compare the DG1 lens with standard single vision spectacles by measuring changes in eye refraction and axial length over time. This clinical trial involves a randomized, double-masked design to ensure unbiased results and will be sponsored by HOYA Lens Thailand LTD. Participants will be randomly assigned to wear either the DG1 spectacle lens or a single vision spectacle lens. Both groups will wear their assigned lenses daily for 36 months. After completing this period, all participants will continue in the study for an additional 12 months to evaluate any rebound effects in myopia progression. The study focuses on lens wear as the main intervention for myopia control. Throughout the study, children will attend scheduled visits for eye measurements including cycloplegic spherical equivalent refraction and axial length assessments. Visual acuity will also be checked at 24 months. Researchers will monitor adherence by confirming that participants wear the spectacles for an average of 10 hours per day. The primary outcomes assessed at 36 months are changes in eye refraction and axial length, with safety and efficacy observed over the total 48-month study duration including the rebound evaluation.

Researchers are evaluating the effectiveness of the MiSight 1 Day contact lens in slowing the progression of myopia in children aged 8 to 12 years in the United States. This multicenter, randomized, double-masked clinical trial lasts four years and aims to confirm the lens's ability to reduce myopia and assess the stability of this effect one year after treatment ends. The study is sponsored by CooperVision, Inc. Participants are randomly assigned to wear either MiSight 1 Day lenses or Proclear 1 day lenses for three years in Part 1 of the study. In Part 2, all participants will wear Proclear 1 day lenses for one year to evaluate the stability of myopia control after discontinuing MiSight lenses. Both subjects and investigators remain unaware of the lens assignments throughout the trial. During the study, participants will undergo regular eye exams including measurements of refractive error and axial length to monitor changes in myopia. Researchers will also assess visual symptoms and how these affect daily activities. The trial includes adherence to lens wear for about 10 hours daily, six days a week, and requires participants to attend scheduled visits for up to four years. Safety and effectiveness data will be collected throughout the study period.